Seattle Women’s: Health, Research, Gynecology
We offer a unique practice that integrates preventative care and medical treatment in addition to cutting-edge research. Our approach creates a standard of excellence in the specialized care of women.
The office is led by Robin Kroll, MD, a recognized leader in women’s healthcare and research.
Our team of professionals is committed to providing you with up-to-date, personalized health care. We offer general, preventative, and specialized services for each stage of a woman’s life.
Clinical research site specializing in women’s health issues. Over the past two decades, Robin Kroll, MD has served as a Principal Investigator for over 200 phase II, III and IV studies.
Help Others in Need
Through our Research with a Mission program, we make anonymous donations to charitable organizations on behalf of each volunteer who participates in a clinical research study.
Participate in Clinical Research!
Browse & Apply for currently enrolling clinical trials in Seattle, Washington. Learn more about your condition, receive access to new treatments, and help your community!
Intrarosa (prasterone) was recently FDA approved to treat moderate to severe painful sexual intercourse (dyspareunia) caused by vulvar and vaginal atrophy (VVA). VVA is a common condition affecting up to 50% of postmenopausal women that results from the loss of estrogen during menopause. This causes the walls of the vagina and surrounding tissues to become
On July 24th, 2018 the US Food and Drug Administration (FDA) approved Elagolix for the treatment of moderate to severe pain associated with endometriosis. Dr. Robin Kroll, director of Seattle Women’s Health Research Gynecology has conducted over a dozen clinical trials with the newly approved endometriosis treatment, Orilissa. The drug, Elagolix — now marketed as
This month, Flibanserin, commonly referred to as “female Viagra,” goes to the full Food and Drug Administration for a vote of approval. In early June, a federal advisory committee to the FDA recommended approval. The final vote is due on or before August 18. The entire concept of Female Sexual Dysfunction (FSD) is controversial. Does